<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04713514</url>
  </required_header>
  <id_info>
    <org_study_id>GINECO-OV244b</org_study_id>
    <secondary_id>2020-004364-25</secondary_id>
    <secondary_id>ENGOT-ov58</secondary_id>
    <nct_id>NCT04713514</nct_id>
  </id_info>
  <brief_title>OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC</brief_title>
  <acronym>TEDOVA</acronym>
  <official_title>Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OSE Immunotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is an international randomized phase II, multicenter, open-label, three&#xD;
      arms trial to assess best supportive care (BSC) vs OSE2101 and vs OSE2101 + pembrolizumab as&#xD;
      maintenance treatment for patients with platinum sensitive relapsed ovarian cancers,&#xD;
      previously treated with 1 to 2 lines of chemotherapy, bevacizumab (if eligible) and a PARP&#xD;
      inhibitor (if eligible).&#xD;
&#xD;
      Patients in Complete Response, Partial Response, or Stable Disease at the end of chemotherapy&#xD;
      with at least 4 cycles of platinum based chemotherapy will be randomized in one of the three&#xD;
      arms (randomization 1:1:2). They will receive one or the two study treatments or BSC until&#xD;
      progression , or intolerance, or up to 2 years (from 1st study treatment dose).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The only therapeutic option for ovarian cancer patients presenting with 1st or 2nd platinum&#xD;
      sensitive relapse post- both bevacizumab and a PARPi is a platinum combination x 6 cycles&#xD;
      followed by observation. There is no currently approved maintenance therapy in this setting.&#xD;
      There is an urgent need for novel strategies for OC in 1st or 2nd relapse post bevacizumab&#xD;
      and PARPi, in particular for novel maintenance strategies to prolong chemotherapy-free&#xD;
      intervals.&#xD;
&#xD;
      One attractive strategy to turn OC from 'cold' tumors into a 'hot' tumor is via vaccination&#xD;
      with tumor associated, or specific epitopes that have been modified to increase MHC and TCR&#xD;
      binding.&#xD;
&#xD;
      OSE2101 is a multi-neoepitope vaccine covering relevant TAAs in OC, including p53 (mutated in&#xD;
      95% of high-grade OC). In addition, the combination of OSE2101with an ICI may most&#xD;
      effectively harness anti-tumor immunity.&#xD;
&#xD;
      If novel IO approaches are proposed in OC, they should be investigated early in the disease&#xD;
      setting when host immunity is still robust, and with low tumor burden (1st or 2nd platinum&#xD;
      sensitive relapse and after 6 cycles of platinum chemotherapy).&#xD;
&#xD;
      The hypothesis being tested is that OSE2101 alone or in combination with Pembrolizumab as&#xD;
      maintenance treatment in patients with ovarian cancer platinum-sensitive relapse could&#xD;
      potentially bring benefit to subjects with high unmet medical need.&#xD;
&#xD;
      A total of 180 patients with HLA-A2 positive phenotype will be randomized using an&#xD;
      Interactive Web Response System (IWRS) according to the following stratification factor:&#xD;
&#xD;
      • Best response to platinum therapy: SD vs PR/CR&#xD;
&#xD;
      In a 1:1:2 ration on the 3 study arms:&#xD;
&#xD;
        -  Arm A (n=45): Observation/best supportive care&#xD;
&#xD;
        -  Arm B (n=45): OSE2101: every 3 weeks until week 18, then every 6 weeks up to week 48,&#xD;
           then every 12 weeks until disease progression, intolerance, patient withdrawal of&#xD;
           consent or up to 2 years&#xD;
&#xD;
        -  Arm C (n=90): OSE2101 + Pembrolizumab: OSE2101 same schedule as arm B plus pembrolizumab&#xD;
           IV every 6 weeks until disease progression, intolerance, patient withdrawal of consent&#xD;
           or up to 2 years&#xD;
&#xD;
      Patient with phenotype HLA-A2 negative will be followed in a separate cohort to record&#xD;
      treatment and outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2021</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>from date to randomization to date of event, assessed up to 4 years</time_frame>
    <description>Progression-free survival (PFS) is the time from randomization to progression measured radiologically using RECIST v1.1 guidelines as reported by the investigator or death, whatever the cause, whichever comes first. Patients alive and free of progression at the cut-off date will be censored at the last tumor assessment date</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>from date to randomization to date of event, assessed up to 4 years</time_frame>
    <description>Objective response rate is defined using RECIST v1.1. Best overall response is defined as the best radiological response observed over the whole evaluation period before progression or subsequent anti-cancer treatment. Proportion of partial and complete responses over the treated population will be computed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>from date to randomization to date of study end, assessed up to 4 years</time_frame>
    <description>Incidence of treatment emergent adverse events will be assessed based on NCI CTC-AE version 5.0 grade and according MedDRA terms (version 23.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to subsequent first treatments (TTST-1)</measure>
    <time_frame>from date to randomization to date of event, assessed up to 4 years</time_frame>
    <description>Time to subsequent treatment (TTST) is the time from randomization to initiation of a first subsequent treatment (including treatment change due to toxicity or investigator's decision). Deaths will be counted as events. Patients alive and not receiving a subsequent treatment will be censored at the last assessment date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to subsequent second treatments (TTST-2)</measure>
    <time_frame>from date to randomization to date of event, assessed up to 4 years</time_frame>
    <description>Time to subsequent treatment (TTST) is the time from randomization to initiation of second subsequent treatment (including treatment change due to toxicity or investigator's decision). Deaths will be counted as events. Patients alive and not receiving a subsequent treatment will be censored at the last assessment date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>from date to randomization to death from any cause, assessed up to 4 years</time_frame>
    <description>Overall Survival (OS) is defined as time from randomization to the date of death, whatever the cause. Patients alive at the cut-of date will be censored at the last date they are known to be alive</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Platinum-sensitive Ovarian Cancer</condition>
  <condition>Relapsed Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A : Best Supportive Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observational arm (Standard of care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B : OSE2101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OSE2101 monotherapy - subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.&#xD;
OSE2101 vaccine is an emulsion of peptides suspension in in Montanide® ISA 51 adjuvant and containing 0.5 mg/mL of each 10 synthetically manufactured peptides (5.0 mg/mL total peptide) in 1.5 mL of emulsion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C : OSE2101 + Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OSE2101 (subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years) + pembrolizumab (400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OSE2101</intervention_name>
    <description>subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.</description>
    <arm_group_label>Arm B : OSE2101</arm_group_label>
    <arm_group_label>Arm C : OSE2101 + Pembrolizumab</arm_group_label>
    <other_name>TEDOPI®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab 25 MG/ML [Keytruda]</intervention_name>
    <description>400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.</description>
    <arm_group_label>Arm C : OSE2101 + Pembrolizumab</arm_group_label>
    <other_name>KEYTRUDA®</other_name>
    <other_name>MK-3475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent document for the study, willing and able to comply&#xD;
             with protocol requirements, including:&#xD;
&#xD;
               1. HLA-A2 phenotype determination by genetic test (blood)&#xD;
&#xD;
               2. participation in translational research in HLA-A2 positive&#xD;
&#xD;
               3. authorization for long term follow up if HLA-A2 negative&#xD;
&#xD;
          2. Histologically or cytologically proven non-mucinous epithelial ovarian cancer&#xD;
&#xD;
          3. Positive HLA-A2 phenotype&#xD;
&#xD;
          4. Age ≥ 18 years&#xD;
&#xD;
          5. ECOG Performance Status (PS) 0-1&#xD;
&#xD;
          6. First or second clinical or radiological relapse of a platine sensitive ovarian cancer&#xD;
             in complete response, partial response or stable disease according to RECIST 1.1 at&#xD;
             the end of a platinum based chemotherapy. Patient must have received at least 4 cycles&#xD;
             of platinum during this chemotherapy&#xD;
&#xD;
          7. Previously treated with a PARP inhibitor or not eligible to PARPi (i.e ineligibility&#xD;
             due to not complete or partial response to chemotherapy)&#xD;
&#xD;
          8. Prior therapy with bevacizumab or with contra-indication to bevacizumab (i.e arterial&#xD;
             thromboembolic events, history of intestinal perforation, any other contra-indications&#xD;
             according to the SmPC)&#xD;
&#xD;
          9. Randomization must be within 8 weeks of last dose of platinum&#xD;
&#xD;
         10. Adequate organ function&#xD;
&#xD;
               -  Adequate marrow function&#xD;
&#xD;
                    -  White blood cell (WBC) ≥ 3000/ mm3&#xD;
&#xD;
                    -  Neutrophils ≥ 1500/ mm3&#xD;
&#xD;
                    -  Platelets ≥ 100 × 103/mm3 (in the absence of transfusion within 2 weeks from&#xD;
                       before randomization)&#xD;
&#xD;
                    -  Haemoglobin ≥ 9 g/dL (in the absence of transfusion within 2 weeks from&#xD;
                       before randomization)&#xD;
&#xD;
               -  Adequate other organ functions&#xD;
&#xD;
                    -  ALT and AST ≤ 2.5 × ULN, unless liver metastases are presents in which case&#xD;
                       they must be ≤ 5.0 × ULN&#xD;
&#xD;
                    -  Total bilirubin ≤ 1.5× ULN (except Gilbert Syndrome: &lt; 3.0 mg/dL)&#xD;
&#xD;
                    -  Serum creatinine ≤ 1.5 × ULN or creatinine clearance (CrCl) ≥ 40 mL/min&#xD;
                       (measured using the Cockcroft-Gault formula below):&#xD;
&#xD;
             Female CrCl = (140 - age in years) × weight in kg × 0.85 72 × serum creatinine in&#xD;
             mg/dL&#xD;
&#xD;
         11. Archival or fresh (if possible) tumor tissue must be available for evaluating relevant&#xD;
             biomarkers. Formalin-fixed paraffin-embedded [FFPE] block preferred, or a minimum of&#xD;
             30 unstained FFPE slides of one archived block is required.&#xD;
&#xD;
         12. Women of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             within 72 hours prior to treatment allocation, and have to use of highly effective&#xD;
             contraception during the treatment period and for at least 120 days after the last&#xD;
             dose of study treatment&#xD;
&#xD;
         13. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
         14. For countries where this will apply to : a subject will be eligible for randomization&#xD;
             in this study only if either affiliated to, or a beneficiary of, a social security&#xD;
             category&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with any immune checkpoint inhibitor, including anti-PD-1, anti-PD-L1,&#xD;
             anti-PD-L2, or anti-CTLA-4 antibody&#xD;
&#xD;
          2. Patient with contra-indications to immune therapies&#xD;
&#xD;
          3. Ongoing immunotherapy (checkpoint inhibition, antigen immunotherapy that would be&#xD;
             scheduled to continue concomitantly to the study)&#xD;
&#xD;
          4. Use of any of the following immunomodulatory agents within 30 days prior to the first&#xD;
             dose of study drug:&#xD;
&#xD;
               -  Systemic corticosteroids (at dose higher than 10 mg/day equivalent prednisone);&#xD;
                  if systemic corticoid use, corticoid must be stopped at least 7 days before study&#xD;
                  treatment start&#xD;
&#xD;
               -  Interferons&#xD;
&#xD;
               -  Interleukins&#xD;
&#xD;
               -  Live vaccine Note: Examples of live vaccines include, but are not limited to, the&#xD;
                  following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, BCG,&#xD;
                  and typhoid vaccine. Seasonal influenza vaccines for injection are generally&#xD;
                  killed virus vaccines and are allowed as other killed vaccines, if done at least&#xD;
                  2 weeks prior the first dose of study drug; however, intranasal influenza&#xD;
                  vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.&#xD;
&#xD;
          5. Prior cancer vaccine therapy&#xD;
&#xD;
          6. Patient eligible for cytoreductive surgery at the time of inclusion&#xD;
&#xD;
          7. Prior radiotherapy within 2 weeks of start of study intervention. Participants must&#xD;
             have recovered from all radiation-related toxicities, not require corticosteroids, and&#xD;
             not have had radiation pneumonitis. A 1-week washout is permitted for palliative&#xD;
             radiation (≤2 weeks of radiotherapy) to non-CNS disease.&#xD;
&#xD;
          8. Patient with active autoimmune disease that has required systemic treatment in the&#xD;
             past 2 years (i.e. with use of disease modifying agents, corticosteroids or&#xD;
             immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic&#xD;
             corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is&#xD;
             not considered a form of systemic treatment and is allowed.&#xD;
&#xD;
          9. History of serious adverse reactions, including anaphylaxis and related symptoms such&#xD;
             as hives and respiratory difficulty following administration of any vaccines, or a&#xD;
             history of hypersensitivity, specifically to any components of study vaccine&#xD;
&#xD;
         10. Prior history of other malignancies other than study disease (except for basal cell or&#xD;
             squamous cell carcinoma of the skin or carcinoma in situ of the cervix or other in&#xD;
             situ cancer considered as cured) unless the patient has been free of the disease for&#xD;
             at least 5 years.&#xD;
&#xD;
         11. Immune-deficient status (patients with HIV, immunosuppressive treatment,&#xD;
             haematological malignancies, and previous organ transplantation)&#xD;
&#xD;
         12. History of (non-infectious) pneumonitis / interstitial lung disease that required&#xD;
             steroids or has current pneumonitis / interstitial lung disease that requires&#xD;
             steroids.&#xD;
&#xD;
         13. History of any chronic hepatitis as evidenced by:&#xD;
&#xD;
               -  Positive test for hepatitis B surface antigen&#xD;
&#xD;
               -  Positive test for qualitative hepatitis C viral load (by polymerase chain&#xD;
                  reaction [PCR]) Note: Subjects with positive hepatitis C antibody and negative&#xD;
                  quantitative hepatitis C by PCR are eligible. History of resolved hepatitis A&#xD;
                  virus infection is not an exclusion criterion&#xD;
&#xD;
         14. Uncontrolled or significant cardiovascular disease including, but not limited to, any&#xD;
             of the following:&#xD;
&#xD;
               -  Myocardial infarction or stroke/transient ischemic attack within the past 6&#xD;
                  months&#xD;
&#xD;
               -  Uncontrolled angina within the past 3 months&#xD;
&#xD;
               -  History of other clinically significant heart disease (eg, cardiomyopathy,&#xD;
                  congestive heart failure with New York Heart Association functional&#xD;
                  classification III-IV, pericarditis, significant pericardial effusion, or&#xD;
                  myocarditis)&#xD;
&#xD;
               -  Any history of clinically significant arrhythmias (such as ventricular&#xD;
                  tachycardia, ventricular fibrillation, or torsades de pointes)&#xD;
&#xD;
               -  QT interval corrected for heart rate using Fridericia's formula (QTcF)&#xD;
                  prolongation &gt; 480 msec&#xD;
&#xD;
               -  Cardiovascular disease-related requirement for daily supplemental oxygen therapy&#xD;
&#xD;
         15. Subjects with known or suspected CNS metastases, untreated CNS metastases, are&#xD;
             excluded. However, subjects with controlled brain metastases will be allowed to&#xD;
             enroll. Controlled brain metastases are defined as no radiographic progression for at&#xD;
             least 4 weeks following radiation and/or surgical treatment (or 4 weeks of observation&#xD;
             if no intervention is clinically indicated), and off of steroids for at least 2 weeks,&#xD;
             and no new or progressive neurological signs and symptoms.&#xD;
&#xD;
         16. Any major surgery within 4 weeks of study drug administration. Subjects must have&#xD;
             recovered from the effects of major surgery or significant traumatic injury at least&#xD;
             14 days before date of randomization.&#xD;
&#xD;
         17. Patients who has severe hypersensitivity (Grade 3 or higher) to pembrolizumab and/or&#xD;
             any of its excipients (refer to the IB for a list of excipients).&#xD;
&#xD;
         18. Patients who has an active infection requiring systemic therapy.&#xD;
&#xD;
         19. Any acute medical condition that in the opinion of the investigator may obscure the&#xD;
             ability to observe the safety or activity of the study vaccine treatment&#xD;
&#xD;
         20. Any mental or psychiatric condition that, in the opinion of the investigator, is&#xD;
             likely to compromise the ability to adhere to the protocol schedule&#xD;
&#xD;
         21. Life expectancy of less than 12 weeks&#xD;
&#xD;
         22. Pregnant or breastfeeding women&#xD;
&#xD;
         23. Concurrent participation in any other investigational study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra LEARY, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GINECO - Gustave Roussy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie Brutto</last_name>
    <phone>+33 1 84 85 20 20</phone>
    <email>tedova-study@arcagy.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>ICO Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Paule AUGEREAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut du cancer Avignon-Provence</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Julien GRENIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thomas GRELLETY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Besançon - Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Elsa KALBACHER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anne FLOQUET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Florence JOLY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ROC -37</name>
      <address>
        <city>Chambray-lès-Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pierre COMBE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laure FAVIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Emilie KACZMAREK, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Limoges - Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Elise DELUCHE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Olivier TREDAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Renaud SABATIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICM - Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michel FABRO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé du Confluent</name>
      <address>
        <city>Nantes</city>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alain LORTHOLARY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Philippe FOLLANA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jérôme ALEXANDRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Diaconesses-Croix Saint-Simon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antoine ANGELLERGUES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Benoît YOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre CARIO - HPCA</name>
      <address>
        <city>Plérin</city>
        <zip>22190</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anne-Claire HARDY-BESSARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thibault DE LA MOTTE ROUGE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO - Centre René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean-Sébastien FRENEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Olivier COLLARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Strasbourg Europe - ICANS</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lauriane EBERST, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Régaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laurence GLADIEFF, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICL - Centre Alexis Vautrin</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yolanda FERNANDEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alexandra LEARY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Maintenance therapy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Cancer vaccine</keyword>
  <keyword>Cold tumor</keyword>
  <keyword>Relapse</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>TEDOPI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

